Quest Diagnostics Inc (DGX) reports a 15.2% revenue increase and raises full-year guidance amid robust performance and strategic expansions.

DGX tops Q2 estimates with 15.2% revenue growth and a strong EPS beat, lifting the stock 3.2% in pre-market trading.

Quest Diagnostics Inc. closed 7.58% below its 52-week high of $182.38, which the company achieved on June 16th.

Quest Diagnostics ranks first in Revenue Growth among its peers. It is second in Gross Profit and Return on Equity. The ...

Quest Diagnostics delivered better-than-expected Q2 earnings results, yet DGX stock stumbled, which opens a contrarian ...

Quest Diagnostics Inc. closed 8.75% short of its 52-week high of $182.38, which the company achieved on June 16th.

Shares of Quest Diagnostics Inc. rallied 7.08% to $178.24 Tuesday, on what proved to be an all-around favorable trading ...

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS ...

Quest Diagnostics Inc. DGX is investing in advanced diagnostics to deliver and scale innovative services that improve patient care and drive growth. The company’s growth strategy includes ...

Detailed price information for Quest Diagnostics Inc (DGX-N) from The Globe and Mail including charting and trades.

Review the current valuation for Quest Diagnostics Inc (DGX:XNYS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.

Detailed price information for Ultragenyx Pharmaceu (RARE-Q) from The Globe and Mail including charting and trades.